Replicel Life Sciences Inc
XTSX:RP

Watchlist Manager
Replicel Life Sciences Inc Logo
Replicel Life Sciences Inc
XTSX:RP
Watchlist
Price: 0.015 CAD 50% Market Closed
Market Cap: CA$722.3k

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Peer Comparison

Country Company Market Cap Operating
Margin
CA
Replicel Life Sciences Inc
XTSX:RP
722.3k CAD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
236.9B USD
Loading...
US
Danaher Corp
NYSE:DHR
165.5B USD
Loading...
CH
Lonza Group AG
SIX:LONN
37.6B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
279.2B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.2B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.8B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Replicel Life Sciences Inc
Glance View

RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. The company is headquartered in Vancouver, British Columbia and currently employs 1 full-time employees. The company went IPO on 2012-09-29. The company is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.

RP Intrinsic Value
0.013 CAD
Overvaluation 13%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top